Inactivating Variants in ANGPTL4 and Risk of Coronary Artery Disease
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Higher-than-normal levels of circulating triglycerides are a risk factor for ischemic cardiovascular disease. Activation of lipoprotein lipase, an enzyme that is inhibited by angiopoietin-like 4 (ANGPTL4), has been shown to reduce levels of circulating triglycerides. METHODS: We sequenced the exons of ANGPTL4 in samples obtain from 42,930 participants of predominantly European ancestry in the DiscovEHR human genetics study. We performed tests of association between lipid levels and the missense E40K variant (which has been associated with reduced plasma triglyceride levels) and other inactivating mutations. We then tested for associations between coronary artery disease and the E40K variant and other inactivating mutations in 10,552 participants with coronary artery disease and 29,223 controls. We also tested the effect of a human monoclonal antibody against ANGPTL4 on lipid levels in mice and monkeys. RESULTS: We identified 1661 heterozygotes and 17 homozygotes for the E40K variant and 75 participants who had 13 other monoallelic inactivating mutations in ANGPTL4. The levels of triglycerides were 13% lower and the levels of high-density lipoprotein (HDL) cholesterol were 7% higher among carriers of the E40K variant than among noncarriers. Carriers of the E40K variant were also significantly less likely than noncarriers to have coronary artery disease (odds ratio, 0.81; 95% confidence interval, 0.70 to 0.92; P=0.002). K40 homozygotes had markedly lower levels of triglycerides and higher levels of HDL cholesterol than did heterozygotes. Carriers of other inactivating mutations also had lower triglyceride levels and higher HDL cholesterol levels and were less likely to have coronary artery disease than were noncarriers. Monoclonal antibody inhibition of Angptl4 in mice and monkeys reduced triglyceride levels. CONCLUSIONS: Carriers of E40K and other inactivating mutations in ANGPTL4 had lower levels of triglycerides and a lower risk of coronary artery disease than did noncarriers. The inhibition of Angptl4 in mice and monkeys also resulted in corresponding reductions in these values. (Funded by Regeneron Pharmaceuticals.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Similarly, inactivating variants in ANGPTL4, a key inhibitor of LPL, have been shown to reduce levels of TGs, LDL-C, and HDL-C. Individuals with these variants exhibit lifelong reductions in circulating TGs and up to a 19% lower risk of CAD [26].”
From Targeting Triglycerides in Cardiovascular Disease Prevention: Evidence, Mechanisms, and Emerging Therapies (2026) · cites this paper as [26]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“rare loss-of-function mutations in the lipoprotein lipase (LPL) gene are associated with higher plasma triglyceride levels and a higher risk of cardiovascular disease”
From Association of Triglyceride-Lowering LPL Variants and LDL-C–Lowering LDLR Variants With Risk of Coronary Heart Disease (2019) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“while rare, loss-of-function mutations in the APOC3, ANGPTL3, and ANGPTL4 genes, which encode for natural inhibitors of LPL, are associated with lower triglyceride levels and a corresponding lower risk of cardiovascular disease.[9][10][11][12][13]”
From Association of Triglyceride-Lowering LPL Variants and LDL-C–Lowering LDLR Variants With Risk of Coronary Heart Disease (2019) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Like mice, humans deficient in ANGPTL3, ANGPTL4, or ANGPTL8 have lower plasma triglycerides (56–58, 163–166).”
From Regulation of lipoprotein metabolism by ANGPTL3, ANGPTL4, and ANGPTL8 (2021) · cites this paper as [56]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Mendelian randomization studies focused on variants in the genes encoding apoAV, apoCIII, lipoprotein lipase (LpL) and the angiopoietin-like proteins 3, 4, and 8 (ANGPTL3, ANGPTL4, and ANGPTL8) have been highly informative.29–35”
10 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data
McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis, K., Kernytsky, A., Garimella, K., Altshuler, D., Gabriel, S., Daly, M., et al. (2010) · Genome Research · doi:10.1101/gr.107524.110 · Cited by 27,895
Cingolani, P., Platts, A., Wang, L. L., Coon, M., Nguyen, T., Wang, L., Land, S. J., Lu, X., & Ruden, D. M. (2012) · Fly · doi:10.4161/fly.19695 · Cited by 11,816
GCTA: a tool for genome-wide complex trait analysis
Yang, J., Lee, S. H., Goddard, M. E., & Visscher, P. M. (2011) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2010.11.011 · Cited by 8,279
Van der Auwera, G. A., Carneiro, M. O., Hartl, C., Poplin, R., del Angel, G., Levy‐Moonshine, A., Jordan, T., Shakir, K., Roazen, D., Thibault, J., et al. (2013) · Current Protocols in Bioinformatics · doi:10.1002/0471250953.bi1110s43 · Cited by 6,687
A solution to the problem of separation in logistic regression
Heinze, G., & Schemper, M. (2002) · Statistics in Medicine · doi:10.1002/sim.1047 · Cited by 2,711
Triglycerides and Cardiovascular Disease: A Scientific Statement From the American Heart Association
Miller, M., Stone, N. J., Ballantyne, C., Bittner, V., Criqui, M. H., Ginsberg, H. N., Goldberg, A. C., Howard, W. J., Jacobson, M. S., Kris-Etherton, P. M., et al. (2011) · Circulation · doi:10.1161/cir.0b013e3182160726 · Cited by 1,871
Li, B., & Leal, S. M. (2008) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2008.06.024 · Cited by 1,527
Triglycerides and cardiovascular disease
Nordestgaard, B. G., & Varbo, A. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61177-6 · Cited by 1,419
Sarwar, N., Danesh, J., Eiriksdottir, G., Sigurdsson, G., Wareham, N., Bingham, S., Boekholdt, S. M., Khaw, K.-T., & Gudnason, V. (2007) · Circulation · doi:10.1161/circulationaha.106.637793 · Cited by 1,408
Research works printed but not linked: 2
- Van der Auwera GA, 2013, Curr Protoc Bioinformatics, 11, 11.10.1
- Romeo S, 2009, J Clin Invest, 119, 70
Cited by
Items 101–200 of 497
Stahel, P., Xiao, C., Hegele, R. A., & Lewis, G. F. (2018) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2017.12.007 · Cited by 75
Targeted pharmacotherapy for ischemia reperfusion injury in acute myocardial infarction
Rout, A., Tantry, U. S., Novaković, M., Sukhi, A., & Gurbel, P. A. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1787987 · Cited by 76
Dijk, W., Ruppert, P. M. M., Oost, L. J., & Kersten, S. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.002426 · Cited by 72
“Specifically, carriers of an inactivating variant of the ANGPTL4 gene have lower plasma triglyceride levels than noncarriers and a lower risk of coronary artery disease (37, 38).”
BackgroundPeloso, G. M., Nomura, A., Khera, A. V., Chaffin, M. D., Won, H., Ardissino, D., Danesh, J., Schunkert, H., Wilson, J. G., Samani, N. J., et al. (2019) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.118.002376 · Cited by 78
Self-citationYingrui, W., Zheng, L., Guoyan, L., & Hong-jie, W. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112690 · Cited by 73
Identification and Characterization of Fenofibrate-Induced Liver Injury
Ahmad, J., Odin, J. A., Hayashi, P. H., Chalasani, N., Fontana, R. J., Barnhart, H., Cirulli, E. T., Kleiner, D. E., & Hoofnagle, J. H. (2017) · Digestive Diseases and Sciences · doi:10.1007/s10620-017-4812-7 · Cited by 69
Suppression of angiopoietin-like 4 reprograms endothelial cell metabolism and inhibits angiogenesis
Chaube, B., Citrin, K. M., Sahraei, M., Singh, A. K., de Urturi, D. S., Ding, W., Pierce, R. W., Raaisa, R., CARDONE, R. L., Kibbey, R. G., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-43900-0 · Cited by 79
“Furthermore, humancarriers ofANGPTL4 E40K showed increased plasma HDL levels rather than decreased 81 .”
Angiopoietin-like 4 Is a Wnt Signaling Antagonist that Promotes LRP6 Turnover
Kirsch, N., Chang, L.-S., Koch, S., Glinka, A., Dolde, C. E., Colozza, G., Benitez, M. D. J., Robertis, E. M. D., & Niehrs, C. (2017) · Developmental Cell · doi:10.1016/j.devcel.2017.09.011 · Cited by 78
“, cardiovascular disease andmetabolic disorder, and renders it a potential drug target (Dewey et al., 2016; Hato et al., 2008; Kersten, 2005).”
BackgroundInfluentialFasting induces ANGPTL4 and reduces LPL activity in human adipose tissue
Ruppert, P. M. M., Michielsen, C. C. J. R., Hazebroek, E. J., Pirayesh, A., Olivecrona, G., Afman, L. A., & Kersten, S. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101033 · Cited by 69
“The importance of ANGPTL4 in the regulation of human plasma triglyceride metabolism is supported by human genetic studies, which have shown that carriers of the E40K mutation and other inactivating variants have reduced plasma triglyceride concentrations and a reduced risk of coronary artery disease [37,38].”
BackgroundAdvances in biological therapies for dyslipidemias and atherosclerosis
Valanti, E.-K., Dalakoura-Karagkouni, K., Siasos, G., Kardassis, D., Eliopoulos, A. G., & Sanoudou, D. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154461 · Cited by 72
Hypertriglyceridemia—causes, significance, and approaches to therapy
Santos-Baez, L. S., & Ginsberg, H. N. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00616 · Cited by 66
“As was the case for ANGPTL3, LOF mutations in ANGPTL4 were associated with lower TG levels and lower risk for CVD in a large cohort study (59).”
ResultTriglyceride metabolism and angiopoietin-like proteins in lipoprotein lipase regulation
Li, J., Li, L., Guo, D., Li, S., Zeng, Y., Liu, C., Fu, R., Huang, M., & Xie, W. (2020) · Clinica Chimica Acta · doi:10.1016/j.cca.2019.12.029 · Cited by 76
Lipoproteins in chronic kidney disease: from bench to bedside
Speer, T., Ridker, P. M., von Eckardstein, A., Schunk, S. J., & Fliser, D. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa1050 · Cited by 69
Liu, Q. K. (2021) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2021.05.007 · Cited by 60
Morelli, M. B., Chavez, C., & Santulli, G. (2019) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2020.1707806 · Cited by 67
“the ANGPTL4 E40K variant and other inactivating mutations in ANGPTL4 to augmented HDL-C levels [3,38].”
BackgroundResultInfluentialDual role of ANGPTL4 in inflammation
Zuo, Y., He, Z., Chen, Y., & Dai, L. (2023) · Inflammation Research · doi:10.1007/s00011-023-01753-9 · Cited by 72
“Consistent with this finding, human monoclonal antibody against ANGPTL4 reduced the circulating TG levels in mice and monkeys [15].”
BackgroundStructure of lipoprotein lipase in complex with GPIHBP1
Arora, R., Nimonkar, A. V., Baird, D., Wang, C., Chiu, C.-H., Horton, P. A., Hanrahan, S., Cubbon, R., Weldon, S., Tschantz, W. R., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1820171116 · Cited by 65
Nordestgaard, L. T., Christoffersen, M., Afzal, S., Nordestgaard, B. G., Tybjærg-Hansen, A., & Frikke-Schmidt, R. (2021) · Clinical Chemistry · doi:10.1093/clinchem/hvaa269 · Cited by 60
Abu‐Farha, M., Cherian, P., Qaddoumi, M. G., Al‐Khairi, I., Devarajan, S., Alanbaei, M., & Abubaker, J. A. (2018) · Lipids in Health and Disease · doi:10.1186/s12944-018-0681-0 · Cited by 63
New Perspectives on Atherogenic Dyslipidaemia and Cardiovascular Disease
Lorenzatti, A. J., & Toth, P. P. (2020) · European Cardiology Review · doi:10.15420/ecr.2019.06 · Cited by 72
Triglycerides and residual risk
Vallejo‐Vaz, A. J., Corral, P., Schreier, L. E., & Ray, K. K. (2020) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000530 · Cited by 65
(2024) · doi:10.1007/s00395-024-01074-w · Cited by 59
Toth, P. P., Philip, S., HULL, M. L., & Granowitz, C. B. (2019) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2019.03.028 · Cited by 64
Björnsson, E., Thorleifsson, G., Helgadóttir, A., Guðnason, T., Guðbjartsson, T., Andersen, K., Grétarsdóttir, S., Ólafsson, Í., Tragante, V., Ólafsson, Ó. H., et al. (2020) · JAMA Cardiology · doi:10.1001/jamacardio.2019.2946 · Cited by 60
Hansen, S. E. J., Madsen, C. M., Varbo, A., Tybjærg-Hansen, A., & Nordestgaard, B. G. (2021) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.08.016 · Cited by 57
McQueen, A. E., Kanamaluru, D., Yan, K., Gray, N. E., Wu, L., Li, M.-L., Chang, A., Hasan, A., Stifler, D., Koliwad, S. K., et al. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.803973 · Cited by 56
“(E40K), decreasing the ability of ANGPTL4 to inhibit LPL (16, 18, 19).”
BackgroundStructures of Angptl3 and Angptl4, modulators of triglyceride levels and coronary artery disease
Biterova, E., Esmaeeli, M., Alanen, H. I., Saaranen, M., & Ruddock, L. W. (2018) · Scientific Reports · doi:10.1038/s41598-018-25237-7 · Cited by 53
PPAR-α agonists are still on the rise: an update on clinical and experimental findings
Ferri, N., Corsini, A., Sirtori, C., & Ruscica, M. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1312339 · Cited by 55
“While the use of LPL gene therapy [108], of antisense apoC3 [109], or, possibly of inactivating monoclonals of ANGPTL4 [110] appears to be of difficult implementation, the present experience with PPAR-α agonists certainly offers a more accessible route to the management of this very frequent clinical condition, namely…”
BackgroundElectronic health records: the next wave of complex disease genetics
Wolford, B. N., Willer, C. J., & Surakka, I. (2018) · Human Molecular Genetics · doi:10.1093/hmg/ddy081 · Cited by 60
New Trends in Dyslipidemia Treatment
Jang, A. Y., Lim, S., Jo, S.-H., Han, S. H., & Koh, K. K. (2021) · Circulation Journal · doi:10.1253/circj.cj-20-1037 · Cited by 52
Cho, D. I., Ahn, M. J., Cho, H. H., Cho, M., Jun, J. H., Kang, B. G., Lim, S. Y., Yoo, S. J., Kim, M. R., Kim, H.-S., et al. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-00937-x · Cited by 59
Morinaga, J., Zhao, J., Endo, M., Kadomatsu, T., Miyata, K., Sugizaki, T., Okadome, Y., Tian, Z., Horiguchi, H., Miyashita, K., et al. (2018) · PLOS ONE · doi:10.1371/journal.pone.0193731 · Cited by 54
Toth, P. P., Fazio, S., Wong, N. D., HULL, M. L., & Nichols, G. A. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13921 · Cited by 69
Rocha, N. A., East, C., Zhang, J., & McCullough, P. A. (2017) · Current Atherosclerosis Reports · doi:10.1007/s11883-017-0697-3 · Cited by 54
Target Populations for Novel Triglyceride-Lowering Therapies
Nordestgaard, A. T., Tybjærg-Hansen, A., Mansbach, H., Kersten, S., Nordestgaard, B. G., & Rosenson, R. S. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.02.035 · Cited by 54
Personalized medicine for cardiovascular diseases
Tada, H., Fujino, N., Nomura, A., Nakanishi, C., Hayashi, K., Takamura, M., & Kawashiri, M. (2020) · Journal of Human Genetics · doi:10.1038/s10038-020-0818-7 · Cited by 64
Hindy, G., Dornbos, P., Chaffin, M. D., Liu, D. J., Wang, M., Selvaraj, M. S., Zhang, D., Park, J., Aguilar-Salinas, C. A., Fulton, L., et al. (2021) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2021.11.021 · Cited by 83
Triglycerides, Atherosclerosis, and Cardiovascular Outcome Studies: Focus on Omega-3 Fatty Acids
Handelsman, Y., & Shapiro, M. D. (2016) · Endocrine Practice · doi:10.4158/ep161445.ra · Cited by 60
“It has recently been shown that mutations in the gene encoding angiopoietin-like 4, a modulator of triglyceride metabolism, result in lower triglyceride levels and lower risk of coronary artery disease (35,36).”
Arca, M., Borghi, C., Pontremoli, R., De Ferrari, G. M., Colivicchi, F., Desideri, G., & Temporelli, P. L. (2018) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2017.11.001 · Cited by 52
“levels and CAD, including loss-of-function alleles in the ANGPTL4 and APOC3 genes [15,22,23].”
BackgroundThe Influence of Big (Clinical) Data and Genomics on Precision Medicine and Drug Development
Denny, J. C., Driest, S. L. V., Wei, W., & Roden, D. M. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.951 · Cited by 56
“19 This group further demonstrated that monoclonal antibody inhibition of Angptl4 in mice reduced triglyceride levels.”
BackgroundHepatokines and Non-Alcoholic Fatty Liver Disease: Linking Liver Pathophysiology to Metabolism
Kim, T. H., Hong, D.-G., & Yang, Y. M. (2021) · Biomedicines · doi:10.3390/biomedicines9121903 · Cited by 61
Lipid and metabolic syndrome traits in coronary artery disease: a Mendelian randomization study
Thomas, D. G., Wei, Y., & Tall, A. R. (2021) · Journal of Lipid Research · doi:10.1194/jlr.p120001000 · Cited by 49
“4F), consistent with prior studies (7, 58).”
Oteng, A.-B., Ruppert, P. M., Boutens, L., Dijk, W., van Dierendonck, X. M. H., Olivecrona, G., Stienstra, R., & Kersten, S. (2019) · Journal of Lipid Research · doi:10.1194/jlr.m094128 · Cited by 46
“Although there is so far no evidence pointing to the occurrence of abdominal lymphadenopathy in humans homozygous for an inactive ANGPTL4 variant (21), currently the therapeutic prospects of whole-body ANGPTL4 inactivation are not very favorable.”
BackgroundLin, J.-R., Sin‐Chan, P., Napolioni, V., Torres, G. G., Mitra, J., Zhang, Q., Jabalameli, M. R., Wang, Z., Nguyen, N., Gao, T., et al. (2021) · Nature Aging · doi:10.1038/s43587-021-00108-5 · Cited by 53
Self-citationBasu, D., & Bornfeldt, K. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00504 · Cited by 52
“Moreover, cynomolgus monkeys and hyperlipidemic rhesus monkeys also display reduced TGs when treated with ANGPTL4-neutralizing antibodies (194).”
BackgroundZwartjes, M., Gerdes, V. E. A., & Nieuwdorp, M. (2021) · Metabolites · doi:10.3390/metabo11080531 · Cited by 58
“, however, found that the loss of function of Angptl4 (missense E40k variant) was associated with reduced triglyceride levels as well as lower coronary artery disease risk [93].”
BackgroundChait, A. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2022.02.010 · Cited by 58
Cummings, B. B., Joing, M. P., Bouchard, P. R., Milton, M. N., Moesta, P. F., Ramanan, V., Lane, A., Hirman, J., Trauger, J. W., Maratos-Flier, E., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)00825-6 · Cited by 49
Role of Neuropilin 1 in COVID-19 Patients with Acute Ischemic Stroke
Al-Thomali, A. W., Al-Kuraishy, H. M., Al-Gareeb, A. I., Albuhadily, A. K., WAARD, M. M. D., Sabatier, J., Khalil, A. A. K., Saad, H. M., & Batiha, G. E. (2022) · Biomedicines · doi:10.3390/biomedicines10082032 · Cited by 51
“Therefore, anti-ANGPTL4 neutralizing antibodies may improve tissue integrity and recovery fr m influenza and pn umococcal pn umonia [119,120].”
BackgroundYoshiji, S., Lu, T., Butler‐Laporte, G., Carrasco-Zanini, J., Su, C., Chen, Y., Liang, K., Willett, J., Wang, S., Adra, D., et al. (2023) · Nature Genetics · doi:10.1016/j.cjca.2023.06.321 · Cited by 65
Haggerty, C. M., James, C. A., Calkins, H. G., Tichnell, C., Leader, J. B., Hartzel, D. N., Nevius, C. D., Pendergrass, S. A., Person, T. N., Schwartz, M. L. B., et al. (2017) · Genetics in Medicine · doi:10.1038/gim.2017.40 · Cited by 50
Self-citationCardiovascular risk in patients with alpha-1-antitrypsin deficiency
on behalf of the COSYCONET investigators, Fähndrich, S., Biertz, F., Karch, A., Kleibrink, B. E., Koch, A., Teschler, H., Welte, T., Kauczor, H., Janciauskiene, S. M., et al. (2017) · Respiratory Research · doi:10.1186/s12931-017-0655-1 · Cited by 50
Mirshahi, U. L., Kim, J., Best, A. F., Chen, Z. E., Hu, Y., Haley, J. S., Golden, A. M., Stahl, R. C., Manickam, K., Carr, A. G., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.0112 · Cited by 49
Self-citationHelkkula, P., Kiiskinen, T., Havulinna, A. S., Karjalainen, J., Koskinen, S., Salomaa, V., Daly, M. J., Palotie, A., Surakka, I., Ripatti, S., et al. (2021) · PLOS Genetics · doi:10.1371/journal.pgen.1009501 · Cited by 47
“Nominal associations (P 0.05) between lower triglyceride levels and protein-truncating variation in ANGPTL8[19] and ANGPTL4[9], as well as between CETP protein-truncating variation and higher HDL cholesterol levels [20], have also been reported.”
BackgroundInfluentialChen, J., Fang, Z., Luo, Q., Wang, X., Warda, M., Das, A., Oldoni, F., & Luo, F. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-023-01993-y · Cited by 47
“Loss-of-function mutations in ANGPTL4 correlate with lower plasma TG levels and a reduced risk of ASCVD [82].”
BackgroundLeth-Espensen, K. Z., Kristensen, K. K., Kumari, A., Winther, A.-M. L., Young, S. G., Jørgensen, T. J. D., & Ploug, M. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2026650118 · Cited by 48
“The first α-helix in ANGPTL4 is required for inactivating LPL (36), and a polymorphic variant in that helix destabilizes ANGPTL4 and reduces its ability to inactivate LPL (10, 11, 19).”
BackgroundGene therapy and genome editing for lipoprotein disorders
Gurevitz, C., Bajaj, A., Khera, A. V., Do, R., Schunkert, H., Musunuru, K., & Rosenson, R. S. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf411 · Cited by 51
“90 However, MAR001, a monoclonal antibody targeting ANGPTL4, demonstrated recently significant reductions in remnant cholesterol and triglycerides in a Phase 2a trial involving 55 participants with hypertriglyceridaemia.”
Chaudhry, R., Viljoen, A., & Wierzbicki, A. S. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1480368 · Cited by 46
Li, G., Zhao, H., Cheng, Z., Liu, J., Li, G., & Guo, Y. (2024) · Journal of Advanced Research · doi:10.1016/j.jare.2024.02.006 · Cited by 49
Gómez‐Ambrosi, J., Corrales, E. P., Catalán, V., Rodríguez, A., Ramírez, B., Romero, S., Vila, N., Ibáñez, P., Margall, M. A., Silva, C., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2084 · Cited by 48
Therapeutic Angiogenesis of Chinese Herbal Medicines in Ischemic Heart Disease: A Review
Guo, D., Murdoch, C. E., Liu, T., Qu, J., Jiao, S., Wang, Y., Wang, W., & Chen, X. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00428 · Cited by 45
“Ang-4 could inhibit the activity of lipoprotein lipase which could hydrolyze triglyceride, thus Ang-4 may be related to the low risk of CAD (Dewey et al., 2016).”
BackgroundAstrocytic lipid metabolism determines susceptibility to diet-induced obesity
Varela, L., Kim, J. G., Fernández-Tussy, P., Aryal, B., Liu, Z. W., Fernández-Hernando, C., & Horvath, T. L. (2021) · Science Advances · doi:10.1126/sciadv.abj2814 · Cited by 43
Severe hypertriglyceridemia: Existing and emerging therapies
Malick, W. A., Do, R., & Rosenson, R. S. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108544 · Cited by 40
Targeting the vasculature in cardiometabolic disease
Boutagy, N. E., Singh, A. K., & Sessa, W. C. (2022) · Journal of Clinical Investigation · doi:10.1172/jci148556 · Cited by 46
The Regulation of Triacylglycerol Metabolism and Lipoprotein Lipase Activity
Wen, Y., Chen, Y., & Konrad, R. J. (2022) · Advanced Biology · doi:10.1002/adbi.202200093 · Cited by 53
The Genetic Architecture of Coronary Artery Disease: Current Knowledge and Future Opportunities
Hartiala, J., Schwartzman, W. S., Gabbay, J., Ghazalpour, A., Bennett, B. J., & Allayee, H. (2017) · Current Atherosclerosis Reports · doi:10.1007/s11883-017-0641-6 · Cited by 47
Landfors, F., Henneman, P., Chorell, E., Nilsson, S. K., & Kersten, S. (2024) · European Heart Journal Open · doi:10.1093/ehjopen/oeae035 · Cited by 42
“DNA-sequencing-based sub-studies from previous papers, 3,47,53,54 were extracted and analysed together with genetic association analyses conducted in the UK Biobank.”
BackgroundMethodInfluentialNovel Therapeutic Targets for Managing Dyslipidemia
Sathiyakumar, V., Kapoor, K., Jones, S. R., Banach, M., Martin, S. S., & Toth, P. P. (2018) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2018.06.001 · Cited by 44
A review of the multifunctionality of angiopoietin-like 4 in eye disease
Yang, X., Cheng, Y., & Su, G. (2018) · Bioscience Reports · doi:10.1042/bsr20180557 · Cited by 44
ANGPTL3 Inhibitors ― Their Role in Cardiovascular Disease Through Regulation of Lipid Metabolism ―
Geladari, E. V., Tsamadia, P., & Vallianou, N. G. (2018) · Circulation Journal · doi:10.1253/circj.cj-18-0442 · Cited by 44
Gutgsell, A. R., Ghodge, S. V., Bowers, A. A., & Neher, S. B. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.005932 · Cited by 41
“Individuals with loss-of-function mutations in ANGPTL4 do not have increased rates of lymphadenopathy, and the animals do not develop this phenotype on standard chow or low-fat diets (25, 26).”
BackgroundInfluentialHDL therapy today: from atherosclerosis, to stent compatibility to heart failure
Sirtori, C. R., Ruscica, M., Calabresi, L., Chiesa, G., Giovannoni, R., & Badimon, J. J. (2019) · Annals of Medicine · doi:10.1080/07853890.2019.1694695 · Cited by 40
“These novel findings are of special interest in in view of the current work on the association of ANGPTL-4 with CV disease risk [60].”
BackgroundRenal Angptl4 is a key fibrogenic molecule in progressive diabetic kidney disease
Srivastava, S. P., Zhou, H., Shenoi, R., Morris, M., Lainez, B., Goedeke, L., Rajendran, B. K., Setia, O., Aryal, B. K., Kanasaki, K., et al. (2024) · Science Advances · doi:10.1126/sciadv.adn6068 · Cited by 41
Targeting apoC-III and ANGPTL3 in the treatment of hypertriglyceridemia
Nurmohamed, N. S., Dallinga‐Thie, G. M., & Stroes, E. S. G. (2020) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2020.1768848 · Cited by 43
“monoclonal antibody (REGN1001) was the first ANGPTL inhibiting treatment tested in both mice and non-human primates and resulted in an almost 50% reduction in TG levels [79].”
BackgroundGabani, M., Shapiro, M. D., & Toth, P. P. (2023) · European Cardiology Review · doi:10.15420/ecr.2023.16 · Cited by 33
Advances in Dyslipidaemia Treatments: Focusing on ApoC3 and ANGPTL3 Inhibitors
Tomlinson, B., Wu, Q., Zhong, Y.-M., & Li, Y. (2024) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2024.13.1.2 · Cited by 46
“21,22 Carriers of inactivating mutations in the ANGPTL4 gene had lower levels of TGs and a lower risk of CHD than did noncarriers, 23 and inhibition of Angptl4 in mice and monkeys with the monoclonal antibody (mAb) REGN1001 also resulted in corresponding reductions in these lipid values.”
BackgroundBittencourt, M. S., Santos, R. D., Staniak, H., Sharovsky, R., Kondapally, R., Vallejo-Vaz, A. J., Ray, K. K., Bensenor, I., & Lotufo, P. (2017) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2017.01.033 · Cited by 38
Strategies to Overcome Residual Risk During Statins Era
Cho, K. I., Yu, J., Hayashi, T., Han, S. H., & Koh, K. K. (2019) · Circulation Journal · doi:10.1253/circj.cj-19-0624 · Cited by 42
The Roles of ANGPTL Families in Cancer Progression
Endo, M. (2019) · Journal of UOEH · doi:10.7888/juoeh.41.317 · Cited by 38
Role of the Gut in Diabetic Dyslipidemia
Stahel, P., Xiao, C., Nahmias, A., & Lewis, G. F. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00116 · Cited by 37
Regulation of plasma triglyceride partitioning by adipose-derived ANGPTL4 in mice
Spitler, K. M., Shetty, S. K., Cushing, E. M., Sylvers-Davie, K. L., & Davies, B. S. J. (2021) · Scientific Reports · doi:10.1038/s41598-021-87020-5 · Cited by 42
Thorin, É., Labbé, P., Lambert, M., Mury, P., Dagher, O., Miquel, G., & Thorin‐Trescases, N. (2023) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2023.06.002 · Cited by 51
Safety and efficacy of therapies for chylomicronemia
Shamsudeen, I., & Hegele, R. A. (2022) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2022.2094768 · Cited by 37
“ANGPTL3; however, preclinical trials have shown an association between ANGPTL4 inhibition and the development of mesenteric adenitis, so this target has not been pursued further [87].”
BackgroundLipoprotein lipase regulates hematopoietic stem progenitor cell maintenance through DHA supply
Liu, C., Han, T., Stachura, D. L., Wang, H., Vaisman, B. L., Kim, J., Klemke, R. L., Remaley, A. T., Rana, T. M., Traver, D. J., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03775-y · Cited by 51
Natarajan, P., Pampana, A., Graham, S. E., Ruotsalainen, S. E., Perry, J. A., de Vries, P. S., Broome, J. G., Pirruccello, J. P., Honigberg, M. C., Aragam, K., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22339-1 · Cited by 38
ANGPTL2 is associated with an increased risk of cardiovascular events and death in diabetic patients
Gellen, B., Thorin‐Trescases, N., Sosner, P., Gand, E., Saulnier, P., Ragot, S., Fraty, M., Laugier, S., Ducrocq, G., Montaigne, D., et al. (2016) · Diabetologia · doi:10.1007/s00125-016-4066-5 · Cited by 44
“ANGPTL4 has also been associated with dyslipidaemia and atherosclerosis in preclinical studies, with interesting data derived from genetic studies [41, 42].”
Metabolic Alterations in Cardiopulmonary Vascular Dysfunction
Smolders, V. F. E. D., Zodda, E., Quax, P. H. A., Carini, M., Barberà, J. A., Thomson, T. M., Tura-Ceide, O., & Cascante, M. (2019) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2018.00120 · Cited by 37
“Individuals with mutations in ANGPTL4 (Angiopoietin-like4) presented a lower risk to develop diabetes mellitus (type2), those with a loss of function in PCSK9 (Proprotein convertase subtilisin/kexin type 9) showed a reduced risk of abdominal aortic aneurysm, and those treated with inhibitors of PDE3B (Phosphodiesteras…”
BackgroundAmor, A. J., Serra‐Mir, M., Martínez‐González, M. Á., Corella, D., Salas‐Salvadó, J., Fitó, M., Estruch, R., Serra‐Majem, L., Arós, F., Babió, N., et al. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.116.004803 · Cited by 45
The lymphatic vascular system: much more than just a sewer
Wilting, J., & Becker, J. (2022) · Cell & Bioscience · doi:10.1186/s13578-022-00898-0 · Cited by 38
Targeting ApoC-III to Reduce Coronary Disease Risk
Khetarpal, S. A., Qamar, A., Millar, J. S., & Rader, D. J. (2016) · Current Atherosclerosis Reports · doi:10.1007/s11883-016-0609-y · Cited by 35
Theofilatos, D., Fotakis, P., Valanti, E., Sanoudou, D., Zannis, V. I., & Kardassis, D. (2018) · Metabolism · doi:10.1016/j.metabol.2018.06.002 · Cited by 38
Oteng, A.-B., Bhattacharya, A., Brodesser, S., Qi, L., Tan, N. S., & Kersten, S. (2017) · Journal of Lipid Research · doi:10.1194/jlr.m074278 · Cited by 34
“In this context, it is relevant to mention that Dewey et al. (16) did not observe any significant difference between E40K carriers and noncarriers in the rates of diagnosis codes for abdominal lymphatic disorders, as well as ascites, peritonitis, malabsorption, abdominal discomfort, or diarrhea.”
BackgroundMethodInfluentialPellegata, N. S., Berriel Diaz, M., Rohm, M., & Herzig, S. (2022) · Cancer and Metastasis Reviews · doi:10.1007/s10555-022-10058-y · Cited by 33
Carruth, E. D., Qureshi, M., Alsaid, A., Kelly, M., Calkins, H. G., Murray, B. A., Tichnell, C., Sturm, A. C., Baras, A., Kirchner, H. L., et al. (2022) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.121.003645 · Cited by 38
Self-citationIntegrated Control of Fatty Acid Metabolism in Heart Failure
Li, X., & Bi, X. (2023) · Metabolites · doi:10.3390/metabo13050615 · Cited by 39
Novel aspects of PCSK9 and lipoprotein receptors in renal disease-related dyslipidemia
Shrestha, P., van de Sluis, B., Dullaart, R. P. F., & van den Born, J. (2018) · Cellular Signalling · doi:10.1016/j.cellsig.2018.12.001 · Cited by 35
An allelic-series rare-variant association test for candidate-gene discovery
McCaw, Z. R., O’Dushlaine, C. T., Somineni, H., Bereket, M. D., Klein, C., Karaletsos, T., Casale, F. P., Koller, D., & Soare, T. W. (2023) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2023.07.001 · Cited by 33
“A candidate-gene study associated rare inactivating mutations in ANGPTL4 with reduced levels of fasting triglycerides and reduced odds of coronary artery disease.(42) Consistent with that work, 25 of the 27 ANGPTL4 rare variants considered in the present”
ResultSelf-citationUnderstanding the Role of Adipokines in Cardiometabolic Dysfunction: A Review of Current Knowledge
Datta, S., Koka, S., & Boini, K. M. (2025) · Biomolecules · doi:10.3390/biom15050612 · Cited by 39
“Circulating ANGPTL8 has been reported to be augmented in systemic inflammatory response syndrome (SIRS), T2D, atherosclerosis, and NAFLD [180,181].”
Kristensen, K. K., Leth-Espensen, K. Z., Kumari, A., Grønnemose, A. L., Winther, A.-M. L., Young, S. G., & Ploug, M. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.702508 · Cited by 35
Hegele, R. A. (2016) · Journal of Lipid Research · doi:10.1194/jlr.c070946 · Cited by 31
“Although earlier studies could not definitively tie this variant to cardioprotection (55), recent genetic findings clearly make this link (10, 53).”
Background
Metadata
- Authors
- Dewey, F. E., Gusarova, V., O’Dushlaine, C., Gottesman, O., Trejos, J., Hunt, C., Van Hout, C. V., Habegger, L., Buckler, D., Lai, K.-M. V., Leader, J. B., Murray, M. F., Ritchie, M. D., Kirchner, H. L., Ledbetter, D. H., Penn, J., Lopez, A., Borecki, I. B., Overton, J. D., Reid, J. G., Carey, D. J., Murphy, A. J., Yancopoulos, G. D., Baras, A., Gromada, J., & Shuldiner, A. R.
- Affiliations
- Regeneron (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-03-24
- Volume
- 374
- Issue
- 12
- Pages
- 1123-1133
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4900689
- OpenAlex
- W2323589075
- Cited by
- 497
- References
- 40
- Citations by year
- 2026: 33 · 2025: 40 · 2024: 38 · 2023: 36 · 2022: 41 · 2021: 63 · 2020: 52 · 2019: 51 · 2018: 53 · 2017: 57 · 2016: 33
- FWCI
- 53.39
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK072488)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- ANGPTL4, loss-of-function mutations, coronary artery disease, triglycerides, HDL cholesterol, lipoprotein lipase, genetic variants, monoclonal antibody inhibition, serum lipids, genetic association studies
- MeSH terms
- Angiopoietin-Like Protein 4, Aged, Animals, Cholesterol, Coronary Artery Disease, Disease Models, Animal, Female, Heterozygote, Humans, Macaca mulatta, Male, Middle Aged, Mutation, Risk Factors, Triglycerides, Gene Silencing, Angiopoietins, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.